Search for content, post, videos

Novo Nordisk demonstrate positive results with Semaglutide

Mads Krogsgaard Thomsen

The results from the SUSTAIN 7 trial, investigating the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin, have been published in The Lancet Diabetes & Endocrinology.

The 40-week trial showed that people with type 2 diabetes treated with once-weekly semaglutide experienced statistically greater reductions in HbA1c and body weight compared to treatment with dulaglutide.

“It is imperative that clinical trial findings are published and made available to clinicians and the scientific community,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. “SUSTAIN 7 is an important head-to-head trial, demonstrating significant efficacy of once-weekly semaglutide vs dulaglutide, and we are pleased that the full manuscript is now available in The Lancet Diabetes & Endocrinology.”

Photo of Mads Krogsgaard Thomsen: Novo Nordisk